bifido

Bacterial
Therapeutics

Pharmaceutical role-playing probiotics

Although current definitions exclude these products from the ‘Probiotics’ category,
we propose that microbial-derived molecules with health benefits could be included
in a sub-category termed “Pharmabiotics” within probiotics.

R&D
Platform

INTEGRATED PLATFORM

EXPRESS-PLATFORM

One-stop industrialization platform based on
microbiome research

PLATFORM
TECHNOLOGY

Immunomodulatory technology based on
human microbiome analysis.

PLATFORM
TECHNOLOGY

Cell factory and drug delivery system
based on engineered Bifidobacterium.

Clinical Trials
Conducting Now

Beyond the functionality of probiotics, its pharmaceutical role is drawing attention around the world. We are continuously conducting human research to prove the effects of the Pharmabiotics in collaboration with university hospitals.

BRAIN

Improvement of cognitive function,
memory and depression in the elderly

Seoul National University
SKIN

Decreased incidence of eczema in infants

Samsung Hospital Pediatrics
GUT

Combination therapy Improved treatment
effect for ulcerative colitis

Medical school of Palermo University Italy
KIDNEY

Improving immunity and inflammation
indicators in kidney dialysis patients

Korea University Hospital Internal Medicine
JOINT

Composition containing bifidobaccterium for
alleviating, preventing of treating RA

Catholic Hospital Internal Medicine
NOSE

Improvement of nasal congestion
and rhinitis symptoms

Seoul National University Internal Medicine

Currently, Bifido Co,. Ltd is performing research for the development of the pharmaceutical Bifidobacterium strain suppressing rheumatoid arthritis (RA) in collaboration with Catholic Hospital RA Center.

Composition for improving, treating or preventing rheumatoid arthritis containing Bifidobacterium
(Korea Patent No.: 10-2074445)
Composition containing bifidobaccterium for alleviating, preventing of treating RA
(US Patent No.: US 10,617,725 B2)